Sugi Predict

Sugi Predict / Compounds / SCHEMBL357155

SCHEMBL357155

SCHEMBL357155

O=[N+]([O-])c1cccc(CN2CCOCC2)c1

nearest known ligand 0.69

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 10/20 0.67
▸ SMN1; SMN2 Q16637 3/20 0.67
▸ LMNA P02545 3/20 0.67
▸ MAPT P10636 3/20 0.67
▸ KCNJ1 P48048 1/20 0.67
▸ KDM4E B2RXH2 4/20 0.65
▸ TDP1 Q9NUW8 1/20 0.65
▸ MEN1 O00255 2/20 0.62
▸ KMT2A Q03164 2/20 0.62
▸ MAPK1 P28482 3/20 0.61
▸ POLB P06746 2/20 0.61
▸ NPSR1 Q6W5P4 1/20 0.60
▸ CTSB P07858 1/20 0.59
▸ NCF1 P14598 1/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30560053 1.00 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2LMNAMAPTKCNJ1
SCHEMBL15800712 0.89 ALDH1A1 (0.78) ALDH1A1SMN1; SMN2LMNAMAPTKDM4E
SCHEMBL922597 0.86 ALDH1A1 (0.70) ALDH1A1SMN1; SMN2LMNAMAPTKDM4E
SCHEMBL4055941 0.86 SIGMAR1 (0.68) ALDH1A1SMN1; SMN2LMNAMAPTKCNJ1
SCHEMBL922442 0.85 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2LMNAMAPTKDM4E
SCHEMBL3568406 0.85 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2LMNAMAPTKDM4E
SCHEMBL19419599 0.84 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2LMNAMAPTKCNJ1
SCHEMBL5578769 0.84 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2LMNAMAPTKDM4E
SCHEMBL2716970 0.82 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2LMNAMAPTKDM4E
SCHEMBL374227 0.82 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2LMNAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 — — EP disclosed
CN-111164074-B Heat shock protein 90 inhibitors 台北医学大学 2024-02-02 — — CN disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
WO-2023237759-A1 DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR ANAGENESIS BIOTECHNOLOGIES (FR) 2023-12-14 — — WO disclosed
EP-4289427-A1 DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR. Anagenesis Biotechnologies (FR) 2023-12-13 — — EP disclosed
WO-2023220541-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS MERCK PATENT GMBH (DE) 2023-11-16 — — WO disclosed
EP-4259145-A1 ALK-5 INHIBITORS AND USES THEREOF Sumitomo Pharma Oncology, Inc. (US) 2023-10-18 — — EP disclosed
US-11746103-B2 ALK-5 inhibitors and uses thereof SUMITOMO PHARMA ONCOLOGY, INC. (US) 2023-09-05 — — US disclosed
US-11746103-B2 ALK-5 inhibitors and uses thereof SUMITOMO PHARMA ONCOLOGY, INC. (US) 2023-09-05 — — US disclosed
US-6723735-B1 TREATMENT OR PREVENTION OF ANXIETY MERCK SHARP & DOHME LTD. 2004-04-20 — — US disclosed
US-20030229068-A1 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use AMGEN INC. 2003-12-11 — — US disclosed
WO-2003101985-A1 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS AMGEN INC. (US) 2003-12-11 — — WO disclosed
EP-1214319-B1 IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2003-11-26 — — EP disclosed
WO-2003045379-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS KINETEK PHARMACEUTICALS, INC. (CA) 2003-06-05 — — WO disclosed
US-20030060453-A1 Pyrazole compounds DERMIRA (CANADA), INC. 2003-03-27 — — US disclosed
WO-2003024967-A2 INDOLIZINES AS KINASE PROTEIN INHIBITORS AVENTIS PHARMA S.A. (FR) 2003-03-27 — — WO disclosed
EP-1214319-A1 IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS Merck Sharp & Dohme Limited (GB) 2002-06-19 — — EP disclosed
WO-2001018000-A1 IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2001-03-15 — — WO disclosed
US-5556969-A Benzodiazepine derivatives MERCK SHARP & DOHME LTD. (GB) 1996-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060453-A1 Pyrazole compounds CCNC, MKI67, CDC25C ALDH1A1 2487/4885SMN1; SMN2 3557/4885LMNA 1653/4885
US-20030229068-A1 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use CASP3, BAX, BAD ALDH1A1 271/4885SMN1; SMN2 318/4885LMNA 942/4885
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS PDXK, DTYMK, HIPK1 ALDH1A1 3576/4885SMN1; SMN2 3927/4885LMNA 4540/4885
US-11746103-B2 ALK-5 inhibitors and uses thereof ACVR1, ALK, ACVRL1 ALDH1A1 773/4885SMN1; SMN2 3355/4885LMNA 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.